Skip to main navigation Skip to search Skip to main content

Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse

  • Andrew Kent
  • , Sumithira Vasu
  • , Derek Schatz
  • , Natalie Monson
  • , Steven Devine
  • , Clayton Smith
  • , Jonathan A. Gutman
  • , Daniel A. Pollyea

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)3102-3108
Number of pages7
JournalBlood Advances
Volume4
Issue number13
DOIs
StatePublished - Jul 14 2020

Keywords

  • Glasdegib maintenance therapy in patients at high risk for relapse did not meaningfully reduce relapse incidence.
  • Key points posttransplantation
  • Use of glasdegib in the posttransplantation setting was complicated by adverse events requiring drug holds and occasional discontinuation

Cite this